Endocyte Chooses CEO Successor
Personalised therapy specialist Endocyte Inc. has appointed Mike Sherman president and CEO succeeding founding CEO Ron Ellis, who has resigned. Sherman has been the company’s chief financial officer since 2006, and took on the additional role of chief operating officer in 2014. Prior to this, he held a variety of executive roles, most recently as vice president of finance and strategic planning at Guidant Corporation.
You may also be interested in...
The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
New Chief Technology Officers named at Seres Therapeutics, ERYTech Pharma and Adicet Bio
Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.